Microbion Corp. Granted US Patent for the Use of Inhaled Pravibismane for Pulmonary Infections
Extends patent protection for Microbion’s proprietary inhaled pravibismane for the treatment of pulmonary infections to 2039.
Extends patent protection for Microbion’s proprietary inhaled pravibismane for the treatment of pulmonary infections to 2039.

Advancing a connected, competitive bioscience ecosystem for Montana’s people, communities, and economy.
© Copyright 2026 | Privacy Policy | Terms of Service | Website & CRM by LocationSync